Oncolytics Biotech Inc ONCY

PR more partial responses form Adlay trial...

[CarbonWarrior]

Wow, there are now more are PR now. Insane that market is not reacting.... to cure for cancer

s of the abstract's data cut-off date (June 2, 2022), ten patients had been treated in the trial, with four achieving a partial response (two confirmed, two unconfirmed) and five showing stable disease (SD). Eight of the nine patients achieving a partial response (PR) or SD remained on study and continued to receive treatment as of the cut-off date. Updated and additional data from the trial will be presented in the poster corresponding to the abstract in accordance with the SABCS embargo policies.

[Noteable]

These results have further added to ONCY's IND-213 two-arm study results which demonstrated that pelareorep is effective when added to the chemotherapy agent paciltaxel (and without the need for any other I/O agent) versus paclitaxel alone. - and that the addition of pelareprep was responsible for the partial and stable disease responses seen. Any global regulatory

[Noteable]

From the SABC submitted abstract ... Among the 10 treated patients, 2 (20%) patients achieved confirmed partial response (PR), 2 (20%) patients achieved unconfirmed PR, and 5 (50%) patients showed stable disease (SD). One patient in DL1 group achieved a confirmed PR and later progressed, and the other 8 patients who had PR or SD continue to receive treatment as of the data cut.

[Noteable]

By the data cutoff date of June 2nd, 2022, a total of 10 female patients were enrolled, with a median age of 58 years (range 36-67). Two (20%) patients had failed more than one prior line of endocrine therapy for advanced/metastatic disease, and 3 (30%) patients were previously treated with a CDK4/6 inhibitor.  8 /10 patients who had PR or SD continue to receive treatment as of the data

[CarbonWarrior]

The one patient that got PR than progressed was going to not recover anyway, that patient was a lost cause... His life got extended nonetheless but we will never be able to measure it.  The rest (89%) got their life extended for sure (either by SD or PR)... As they live on and on, this baby should grow. Not sure why this company is not releasing a more aggressive news release... Such as...

[Noteable]

Since there has been no clinical trial assessing AN1004 in Chinese population, the Adlai Nortye bridging study (REO 026-1) was initiated to evaluate its safety and tolerability in combination with PTX in Chinese patients with HR+/HER2- advanced/metastatic breast cancer. The conclusion of the study was that: To date (June 2, 2022), intravenous administration of AN1004 plus PTX was demonstrated to